Literature DB >> 25281461

Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.

Guo Yu1, Qing-Shan Zheng2, Da-Xin Wang3, Hong-Hao Zhou4, Guo-Fu Li5.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25281461     DOI： 10.1016/S1470-2045(14)70458-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  Oral targeted therapy for cancer.

Authors:  Christine Carrington
Journal:  Aust Prescr       Date:  2015-10-01

2.  Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?

Authors:  Guo Yu; Dan-Na Wu; Yan Gong; Guo-Fu Li; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2018-03-13       Impact factor: 2.953

Review 3.  Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.

Authors:  Guo Yu; Guo-Fu Li; John S Markowitz
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-09       Impact factor: 2.576

4.  Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.

Authors:  Mingxiang Liao; Jie Zhou; Kenton Wride; Denise Lepley; Terri Cameron; Mark Sale; Jim Xiao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-18       Impact factor: 2.569

5.  The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.

Authors:  Vincent Yi-Fong Su; Kuang-Yao Yang; Ting-Yu Huang; Chia-Chen Hsu; Yuh-Min Chen; Jiin-Cherng Yen; Yueh-Ching Chou; Yuh-Lih Chang; Chien-Hui He
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.